Glucagon-like peptide-1 receptor agonists for the treatment of opioid use disorders: a systematic review

GLP-1 receptor agonists reduced opioid-seeking behavior and self-administration in preclinical studies.

• GLP-1 receptor agonists, such as exenatide and liraglutide, showed a significant decrease in opioid-seeking behavior in preclinical models (< 0.05).
• Opioid self-administration was also significantly reduced in preclinical paradigms with GLP-1 receptor agonist treatment (< 0.05).
• In human studies, GLP-1 administration was associated with a reduction in the risk of opioid overdose, with an adjusted incidence rate ratio of 0.60 (95% CI [0.43, 0.83]).
• Both preclinical and clinical data suggest that GLP-1 receptor agonists may influence opioid-related behaviors and overdose risk.
• Further well-controlled studies are necessary to clarify the clinical significance of these findings for individuals with opioid use disorders.

AI simplified